All
4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD
March 11th 20254D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.